Background Decitabine is widely used in the treatment of acute myeloid leukemia (AML) in
elderly patients. Low-dose Vitamin C has also been indicated to induce DNA demethylation …

Background TP53 mutation (TP53mut) confers an adverse prognosis in acute myeloid
leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older …

The majority of patients with acute myeloid leukemia (AML) are elderly and have a poor
prognosis despite induction therapy. Decitabine, a DNA-hypomethylating agent that induces …

Abstract Background The methylation inhibitor 5-Aza-2′-deoxycytidine (decitabine, DAC)
has a great therapeutic value for acute myeloid leukemia (AML) and myelodysplastic …

This study aimed to investigate the efficacy and mechanism of decitabine (DAC) and all-
trans retinoic acid (ATRA) in elderly acute myeloid leukemia (AML) patients and cultured …

Loss-of-function mutations in the DNA demethylase TET2 are associated with the
dysregulation of hematopoietic stem cell differentiation and arise in approximately 10% of de …

Background Acute myeloid leukemia (AML) is predominantly a disease of older patients with
a poor long-term survival. Approval of decitabine (DAC) in the European Union (EU) in 2012 …

Elderly patients with acute myeloid leukemia (AML) have limited treatment options
concerned about their overall fitness and potential treatment related mortality. Although a …

Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved
for older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy based …

Introduction. Most acute myeloid leukemia (AML) patients with adverse prognosis either fail
to achieve complete remission (CR) or relapse after short-term remission, new strategies are …